Can-Fite BioPharma (CANF) Research & Development (2014 - 2023)
Can-Fite BioPharma's (CANF) quarterly Research & Development came in at -$1.3 million in Q4 2023, down 87.98% YoY from -$10.5 million in Q4 2022, and up 2.46% on a QoQ basis from -$1.3 million in Q3 2023.
Can-Fite BioPharma (CANF) Research & Development (2014 - 2023) Analysis & Trends
Can-Fite BioPharma (CANF) has 10 years of Research & Development data on file, last reported at -$1.3 million in Q4 2023.
- Quarterly Research & Development fell 87.98% year-over-year to -$1.3 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$6.0 million (changed 0.0% YoY) and the FY2025 annual result came in at -$6.7 million, down 16.26% from the prior year.
- Research & Development rose to -$1.3 million in Q4 2023, from -$1.3 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $1.4 million in Q1 2019 to a low of -$5.4 million in Q2 2019.
- A 5-year average of -$2.2 million and a median of -$2.0 million in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2020 — Research & Development sank 361.33% — and 2022, when it jumped 78.27%.
- Tracing CANF's Research & Development over 5 years: stood at -$4.0 million in 2019, then advanced by 26.87% to -$2.9 million in 2020, then decreased by 7.08% to -$3.1 million in 2021, then surged by 78.27% to -$674000.0 in 2022, then sank by 87.98% to -$1.3 million in 2023.
- The last three Research & Development figures came in at -$1.3 million (Q4 2023), -$1.3 million (Q3 2023), and -$1.4 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Can-Fite BioPharma | 2.82 Mn | -8.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -1.27 Mn |
| Sep 30, 2023 | -1.30 Mn |
| Jun 30, 2023 | -1.36 Mn |
| Mar 31, 2023 | -2.06 Mn |
| Dec 31, 2022 | -674,000.00 |
| Sep 30, 2022 | -2.04 Mn |
| Jun 30, 2022 | -1.45 Mn |
| Mar 31, 2022 | -1.82 Mn |
| Dec 31, 2021 | -3.10 Mn |
| Sep 30, 2021 | -2.94 Mn |
| Jun 30, 2021 | -2.51 Mn |
| Mar 31, 2021 | -1.30 Mn |
| Dec 31, 2020 | -2.90 Mn |
| Sep 30, 2020 | -2.00 Mn |
| Jun 30, 2020 | -3.28 Mn |
| Mar 31, 2020 | -3.77 Mn |
| Dec 31, 2019 | -3.96 Mn |
| Sep 30, 2019 | -3.06 Mn |
| Jun 30, 2019 | -5.40 Mn |
| Mar 31, 2019 | 1.44 Mn |